Literature DB >> 20890707

Hotline sessions and clinical trial updates presented at the European Society of Cardiology Congress in Stockholm 2010.

Matthias Lenski1, Felix Mahfoud, Christian Werner, Axel Bauer, Michael Böhm.   

Abstract

This article gives an overview on several novel clinical trials in the field of cardiovascular (CV) medicine which were presented during the hotline sessions and clinical trial updates at the European Society of Cardiology Congress, held in Stockholm, Sweden, from 28th August to 1st September 2010. The data have been presented by leading experts in the accordant field with relevant positions in the trials. Unpublished reports should be considered as preliminary data as the analysis may change in the final publications. The summaries presented in the manuscript were generated from the oral presentations and should provide the readers with the most comprehensive information on diagnostic and therapeutic development in CV medicine similar as previously reported Schirmer SH et al.

Mesh：

Year:  2010        PMID： 20890707     DOI： 10.1007/s00392-010-0238-3

Source DB:  PubMed          Journal:  Clin Res Cardiol        ISSN： 1861-0684            Impact factor:   5.460


  22 in total

1.  Guidelines on myocardial revascularization.

Authors:  William Wijns; Philippe Kolh; Nicolas Danchin; Carlo Di Mario; Volkmar Falk; Thierry Folliguet; Scot Garg; Kurt Huber; Stefan James; Juhani Knuuti; Jose Lopez-Sendon; Jean Marco; Lorenzo Menicanti; Miodrag Ostojic; Massimo F Piepoli; Charles Pirlet; Jose L Pomar; Nicolaus Reifart; Flavio L Ribichini; Martin J Schalij; Paul Sergeant; Patrick W Serruys; Sigmund Silber; Miguel Sousa Uva; David Taggart
Journal:  Eur Heart J       Date:  2010-08-29       Impact factor: 29.983

2.  Randomized trial to compare bilateral vs. single internal mammary coronary artery bypass grafting: 1-year results of the Arterial Revascularisation Trial (ART).

Authors:  David P Taggart; Douglas G Altman; Alastair M Gray; Belinda Lees; Fiona Nugara; Ly-Mee Yu; Helen Campbell; Marcus Flather
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983

3.  Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure.

Authors:  Finlay A McAlister; Natasha Wiebe; Justin A Ezekowitz; Alexander A Leung; Paul W Armstrong
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

Review 4.  Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence.

Authors:  Joachim R Ehrlich; Stefan H Hohnloser; Stanley Nattel
Journal:  Eur Heart J       Date:  2005-11-25       Impact factor: 29.983

5.  COlchicine for the Prevention of the Post-pericardiotomy Syndrome (COPPS): a multicentre, randomized, double-blind, placebo-controlled trial.

Authors:  Massimo Imazio; Rita Trinchero; Antonio Brucato; Maria Elena Rovere; Anna Gandino; Roberto Cemin; Stefania Ferrua; Silvia Maestroni; Edoardo Zingarelli; Alberto Barosi; Caterina Simon; Fabrizio Sansone; Davide Patrini; Ettore Vitali; Paolo Ferrazzi; David H Spodick; Yehuda Adler
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983

6.  ISAR-REACT 3A: a study of reduced dose of unfractionated heparin in biomarker negative patients undergoing percutaneous coronary intervention.

Authors:  Stefanie Schulz; Julinda Mehilli; Franz-Josef Neumann; Tibor Schuster; Steffen Massberg; Christian Valina; Melchior Seyfarth; Jürgen Pache; Karl-Ludwig Laugwitz; Hans-Joachim Büttner; Gjin Ndrepepa; Albert Schömig; Adnan Kastrati
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983

7.  Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study.

Authors:  Karl Swedberg; Michel Komajda; Michael Böhm; Jeffrey S Borer; Ian Ford; Ariane Dubost-Brama; Guy Lerebours; Luigi Tavazzi
Journal:  Lancet       Date:  2010-09-11       Impact factor: 79.321

8.  Low-dose vs standard-dose unfractionated heparin for percutaneous coronary intervention in acute coronary syndromes treated with fondaparinux: the FUTURA/OASIS-8 randomized trial.

Authors:  Philippe Gabriel Steg; Sanjit S Jolly; Shamir R Mehta; Rizwan Afzal; Denis Xavier; Hans-Jurgen Rupprecht; Jose L López-Sendón; Andrzej Budaj; Rafael Diaz; Alvaro Avezum; Petr Widimsky; Sunil V Rao; Susan Chrolavicius; Brandi Meeks; Campbell Joyner; Janice Pogue; Salim Yusuf
Journal:  JAMA       Date:  2010-08-31       Impact factor: 56.272

9.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

10.  Double-blind, placebo-controlled Phase II studies of the protease-activated receptor 1 antagonist E5555 (atopaxar) in Japanese patients with acute coronary syndrome or high-risk coronary artery disease.

Authors:  Shinya Goto; Hisao Ogawa; Masaru Takeuchi; Marcus D Flather; Deepak L Bhatt
Journal:  Eur Heart J       Date:  2010-08-30       Impact factor: 29.983
View more
  2 in total

1.  Hotline update of clinical trials and registries presented at the at the European Society of Cardiology Congress in Paris 2011.

Authors:  K Walenta; J M Sinning; C Werner; M Böhm
Journal:  Clin Res Cardiol       Date:  2011-09-30       Impact factor: 5.460

2.  Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2011.

Authors:  K Walenta; J M Sinning; N Werner; M Böhm
Journal:  Clin Res Cardiol       Date:  2011-04-23       Impact factor: 5.460
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.